You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company already offers an antibody test, Anti-SARS-CoV-2 Rapid Test, that it is distributing for its Chinese joint venture partner Autobio Diagnostics.
More than a dozen studies have been published to date directly comparing molecular diagnostic COVID-19 tests, with some detecting differences, mostly in sensitivity.
The Minneapolis-based firm believes the assay can successfully serve as a clinical indicator for patients at risk of developing high-grade prostate cancer (HGPC), thereby improving prostate cancer management.
The firm also received the CE mark for the test, which uses a reformulated buffer and takes less time to process than a test requiring an RNA extraction step.
The expansion increases the number of PCR instruments and types of reagents and consumables labs can use to run the Applied Biosystems TaqPath COVID-19 Combo Kit.
Meridian has been providing essential components, including reagents, for multiple SARS-CoV-2 molecular and serology tests.
Replacing nasopharyngeal swabs with saliva samples or nasal swabs could increase throughput and convenience, as well as relieve reagent and equipment shortages.
BGI will establish six so-called Huo-Yan COVID-19 testing labs in Saudi Arabia, based on the emergency lab the firm set up in Wuhan, China in February.
The test is designed for the detection of nucleic acid from SARS-CoV-2 in nasopharyngeal, oropharyngeal, nasal, and mid-turbinate nasal swab specimens as well as sputum.
Several labs and at least one company have been working on assays that add samples directly to the PCR reaction and don't require RNA extraction, a time-consuming step.